AlzBiomarker
Progressive Supranuclear Palsy vs Alzheimer's Disease: tau-p181 (CSF)
Meta-analysis showed that levels of tau-p181 in the cerebrospinal fluid of people with progressive supranuclear palsy are less than half those in people with Alzheimer's disease (effect size = 0.427, p <0.0001). For comparison, the level of CSF tau-p181 in control subjects is about half that of AD patients.
Loading data...